Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Floege

Showing results (11-20 of 156) with videos related to

Pageof 16
Sort By:
Kidney International|March 22, 2001
Platelet-derived growth factor: a new clinical target on the horizonJ Floege, T Ostendorf
Herz|February 10, 2021
Heart failure in advanced chronic kidney disease: treatment rationaleN Marx, J Floege
Journal of Nephrology|October 26, 2005
Present and future therapy options in IgA-nephropathyJ Floege, F Eitner
Der Internist|May 11, 2017
[Choosing wisely recommendations in nephrology]J Galle, J Floege
Medizinische Klinik (Munich, Germany : 1983)|June 22, 1999
[Aptamers: a novel approach to intervention studies and development of novel therapeutic approaches]T Ostendorf, J Floege
Nephron|January 1, 1996
Beta-2-microglobulin-associated amyloidosisJ Floege, G Ehlerding
Kidney International. Supplement|February 13, 2001
beta2-microglobulin-derived amyloidosis: an updateJ Floege, M Ketteler
Deutsche Medizinische Wochenschrift (1946)|July 18, 2013
[Glomerulonephritis]J Floege, A Bienert
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 19, 2015
Renal allograft fibrosis: biology and therapeutic targetsP Boor, J Floege
Current Opinion in Nephrology and Hypertension|May 1, 1993
Cytokines in renal inflammationJ Floege, R J Johnson
Pageof 16

Showing results (11-20 of 156) with videos related to

Sort By:
Pageof 16
Kidney International|March 22, 2001
Platelet-derived growth factor: a new clinical target on the horizonJ Floege, T Ostendorf
Herz|February 10, 2021
Heart failure in advanced chronic kidney disease: treatment rationaleN Marx, J Floege
Journal of Nephrology|October 26, 2005
Present and future therapy options in IgA-nephropathyJ Floege, F Eitner
Der Internist|May 11, 2017
[Choosing wisely recommendations in nephrology]J Galle, J Floege
Medizinische Klinik (Munich, Germany : 1983)|June 22, 1999
[Aptamers: a novel approach to intervention studies and development of novel therapeutic approaches]T Ostendorf, J Floege
Nephron|January 1, 1996
Beta-2-microglobulin-associated amyloidosisJ Floege, G Ehlerding
Kidney International. Supplement|February 13, 2001
beta2-microglobulin-derived amyloidosis: an updateJ Floege, M Ketteler
Deutsche Medizinische Wochenschrift (1946)|July 18, 2013
[Glomerulonephritis]J Floege, A Bienert
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 19, 2015
Renal allograft fibrosis: biology and therapeutic targetsP Boor, J Floege
Current Opinion in Nephrology and Hypertension|May 1, 1993
Cytokines in renal inflammationJ Floege, R J Johnson
Pageof 16